Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart.

Slides:

Advertisements

Similar presentations

Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.

Advertisements

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.

© 2002, Wellsource Inc. C-Reactive Protein A New Test for Cardiovascular Risk Prepared by Don Hall, DrPH Wellsource Inc.

Cholesterol-Lowering Therapy in Women and Elderly Patients with Myocardial Infarction or Angina Pectoris Findings From the Scandinavian Simvastatin Survival.

Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.

Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.

Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.

SPARCL – Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Jim McMorran Coventry GP GP with Specialist Interest in Diabetes and.

Rosuvastatin, Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Cholesterol Response: the JUPITER Trial Z. Awan, N.G. Seidah, J.G.

Amarenco P, Labreuche J. Lancet Neurol 2009;8:

Clinical Trial Results. org METEOR Trial Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. John R.

Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.

Date of download: 5/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: 2013 ACC/AHA Guideline on the Treatment of Blood.

Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Primary Prevention With Statins: ACC/AHA Risk-Based.

Presentation Title R3 이지영 / 김 수 중교 수 님. Introduction Lowering LDL cholesterol levels with statins : Reduce the risk of cardiovascular disease Vascular.

Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Optimal low-density lipoprotein is 50 to 70 mg/dl:

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Varespladib and Cardiovascular Events in Patients.

The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.

Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pregnancy-associated plasma protein-A levels in.

Date of download: 6/26/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Influence of Left Ventricular Ejection Fraction.

Date of download: 6/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Test in Context: High-Sensitivity C-Reactive Protein.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: A Proposal to Incorporate Trial Data Into a Hybrid.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Atherothrombosis J Am Coll Cardiol. 2012;60(10):

Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.

Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Next Steps in Primary Prevention of Coronary Heart.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: What resting heart rate should one aim for when.

Dr John Cox Diabetes in Primary Care Conference Cork

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:

Copyright © 2017 American Academy of Pediatrics.

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

Cholesterol practice questions

From: Treatment of Blood Cholesterol to Reduce Risk for Atherosclerotic Cardiovascular DiseaseGrand Rounds Discussion From the Beth Israel Deaconess Medical.

Copyright © 2015 by the American Osteopathic Association.

by Salim Yusuf, and Sonia Anand

Oxygen Therapy in Ischemic Stroke

Site Selection and Performance in Clinical Trials

Behavior and Biology: The Basic Sciences for AHA Action

2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? Sripal Bangalore, MD,

TNT Study: Baseline Characteristics of the Patients

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

Quantitating the Dose of Physical Activity in Secondary Prevention: Relation of Exercise Intensity to Survival Barry A. Franklin, PhD Mayo Clinic Proceedings

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised.

APOC3, Coronary Disease, and Complexities of Mendelian Randomization

When Guidelines Cause Hypertension

Intensive versus moderate statin therapy and early graft occlusion after coronary bypass surgery: The Aggressive Cholesterol Therapy to Inhibit Vein Graft.

Contemporary Evidence-Based Guidelines

LDL Cholesterol.

These slides highlight a presentation from a Special Session of the Late-Breaking Clinical Trials sessions during the American College of Cardiology 2005.

Potential mechanisms whereby statins may reduce the risk of stroke

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials Cholesterol.

C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study Heart Protection.

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

The Heart Rhythm Society Meeting Presented by Dr. Johan De Sutter

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk Terry.

Rhanderson Cardoso, MD, Roger S

Volume 87, Issue 1, Pages (January 2015)

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target American.

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Delahoy PJ, et al. Clin Ther 2009;31:236-44

The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.

The ACCORD Study Group. NEJM 2010; Epub March 14

Diabetes, prediabetes, and cardiovascular risk: Shifting the paradigm

The Journal of Thoracic and Cardiovascular Surgery

Section 6: Update on lipid treatment guidelines

The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.

Presentation transcript:

Beyond the Laboratory by Julian P.J. Halcox, and John E. Deanfield Circulation Volume 109(21 suppl 1):II-42-II-48 June 1, 2004 Copyright © American Heart Association, Inc. All rights reserved.

Figure 1. A, Kaplan–Meier estimates for stroke in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Trial. Julian P.J. Halcox, and John E. Deanfield Circulation. 2004;109:II-42-II-48 Copyright © American Heart Association, Inc. All rights reserved.

Figure 2. Effect of simvastatin therapy compared with placebo according to LDL cholesterol and total cholesterol levels at enrollment in the Heart Protection Study, demonstrating similar relative reduction in major cardiovascular events in subjects with high, intermediate, and low baseline LDL and total cholesterol levels. Julian P.J. Halcox, and John E. Deanfield Circulation. 2004;109:II-42-II-48 Copyright © American Heart Association, Inc. All rights reserved.

Figure 3. Decrease in event rates with successively lower concentrations of LDL cholesterol achieved with statin or placebo in major primary and secondary prevention trials. Julian P.J. Halcox, and John E. Deanfield Circulation. 2004;109:II-42-II-48 Copyright © American Heart Association, Inc. All rights reserved.

Figure 4. LDL and high-sensitivity (assay) C-reactive protein levels (left and right panels, respectively) over 12 months in the intensive LDL-reduction (circles) and modest LDL-reduction (squares) groups. Julian P.J. Halcox, and John E. Deanfield Circulation. 2004;109:II-42-II-48 Copyright © American Heart Association, Inc. All rights reserved.